A major hurdle in EV-based therapies is the “yield gap” โ standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs.
In our latest co-authored study published in ๐ฆ๐๐ฒ๐บ ๐๐ฒ๐น๐น๐ ๐ง๐ฟ๐ฎ๐ป๐๐น๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ถ๐ป๐ฒ, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA scientists, addressed this challenge head-on. Together, we applied deep molecular fingerprinting and in vivo potency studies to validate a new large-scale production protocol for Parkinsonโs Disease (PD) therapies.
By leveraging our specialized transcriptomic and proteomic pipelines, we analyzed how production and purification methods shape the EV “message”:
โ
๐ฏ๐ ๐๐. ๐ฎ๐ ๐๐ผ๐บ๐ฝ๐ฎ๐ฟ๐ถ๐๐ผ๐ป: Our analysis revealed that while mRNA and proteomic content remained stable, culture conditions (3D bioreactors vs. 2D flasks) significantly influenced the ๐บ๐ถ๐ฅ๐ก๐ ๐ฝ๐ฟ๐ผ๐ณ๐ถ๐น๐ฒ๐ of the EVs.
โ
๐จ๐น๐๐ฟ๐ฎ๐ฐ๐ฒ๐ป๐๐ฟ๐ถ๐ณ๐๐ด๐ฎ๐๐ถ๐ผ๐ป ๐๐. ๐ง๐๐-๐ฆ๐๐: protein and miRNA profiles change significantly depending on the method of purification, while the mRNA cargo remained stable.
โ
๐ ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐๐ถ๐ป๐ด๐ฒ๐ฟ๐ฝ๐ฟ๐ถ๐ป๐๐ถ๐ป๐ด ๐ฎ๐ป๐ฑ ๐๐๐ป๐ฐ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ป๐ฎ๐น๐๐๐ถ๐: We identified enrichment in miRNAs associated with ๐ฎ๐ป๐๐ถ-๐ผ๐
๐ถ๐ฑ๐ฎ๐๐ถ๐๐ฒ and ๐ฎ๐ป๐๐ถ-๐ถ๐ป๐ณ๐น๐ฎ๐บ๐บ๐ฎ๐๐ผ๐ฟ๐ ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ฒ๐, providing a molecular basis for the therapeutic effects seen in vivo.
โ
๐ฃ๐ฟ๐ผ๐๐ฒ๐ป ๐๐ณ๐ณ๐ถ๐ฐ๐ฎ๐ฐ๐: The study demonstrated that EVs produced via this new 463-fold scale-up protocol were just as effective as standard methods in improving gait and cognitive functions in PD models.
This research proves that with the right scale-up strategy and rigorous molecular validation, we can produce the high-quality, high-volume EV treatments needed for the future of regenerative neuro-medicine.
Congratulations to the authors on this impressive achievement! ๐
